Cubist Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cubist Pharmaceuticals, Inc.
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
- Other Names / Subsidiaries
- Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.